3 research outputs found
CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy
The
unsatisfied results of cancer therapy are caused by many issues
and metastasis of cancer cells is one of the major challenge. It has
been reported that inhibiting the SDF1/CXCR4 interaction can significantly
reduce the metastasis of breast cancer cells to regional lymph nodes
and lung. Herein, a nanogel system equipped with the FDA-approved
CXCR4 antagonist AMD3100 was developed and evaluated for its combined
antimetastatic and tumor targeting effects. Briefly, a bioreducible
cross-linked dextrin nanogel (DNG) coated with AMD3100 was designed
to possess multiple functions, including CXCR4 chemokine targeting,
inhibition of tumor metastasis, and reduction-responsive intracellular
release of doxorubicin (DOX) to reduce the cells proliferation. The
in vitro results confirmed that the DOX-loaded AMD3100-coated dextrin
nanogel (DOX-AMD-DNG) was more effectively taken up by 4T1 breast
cancer cells than DOX-DNG and was significantly more cytotoxic to
4T1 cells than DOX-DNG. In biodistribution studies, the stronger fluorescence
intensity of Cy7-AMD-DNG than Cy7-DNG further confirmed that AMD3100
mediated tumor targeting in vivo. AMD3100-coated DOX-DNG also exhibited
a distinct antimetastatic effect and CXCR4 antagonistic activity by
inhibiting CXCR4-mediated cell invasion in 4T1 and U2OS cells. Moreover,
DOX-AMD-DNG displayed superior anticancer activity and antimetastatic
effects in orthotopic breast cancer-bearing Balb/C mice. In summary,
the multifunctional DOX-AMD-DNG can effectively target the tumor site
and dually impede cancer progression and metastasis
Sesquiterpene-neolignans from <i>Manglietia hookeri</i>
<p>The comet assay-guided fractionation of the twigs of <i>Manglietia hookeri</i> resulted in the isolation of three sesquiterpene-neolignans, including a new one 5-allyl-2-(4-allyl-phenoxy)-3-[7-(1-hydroxy-1-methyl-ethyl)-1, 4a-dimethyl-decahydro-naphthalen-1-yloxy]-phenol (<b>1</b>), and eudesobovatol A (<b>2</b>) and eudesobovatol B (<b>3</b>), together with three lignans, obovatol (<b>4</b>), honokiol (<b>5</b>) and magnolol (<b>6</b>). Their structures were elucidated on the basis of spectral analysis and by comparison with related literature data. Compounds <b>1</b>, <b>4</b>–<b>6</b> showed a protective effect on UV inductive DNA damage in mice lymphocyte cells, while compound <b>1</b> indicated the smallest Olive Tail Moment 7.34 ± 2.09 at 6 × 10<sup>−6</sup> μM.</p
Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase‑1 in Cells
Methionine
aminopeptidases (MetAPs), which remove the initiator
methionine from nascent peptides, are essential in all organisms.
While MetAP2 has been demonstrated to be a therapeutic target for
inhibiting angiogenesis in mammals, MetAP1 seems to be vital for cell
proliferation. Our earlier efforts identified two structural classes
of human MetAP1 (<i>Hs</i>MetAP1)-selective inhibitors (<b>1</b>–<b>4</b>), but all of them failed to inhibit
cellular <i>Hs</i>MetAP1. Using MnÂ(II) or ZnÂ(II) to activate <i>Hs</i>MetAP1, we found that <b>1</b>–<b>4</b> could only effectively inhibit purified <i>Hs</i>MetAP1
in the presence of physiologically unachievable concentrations of
CoÂ(II). In an effort to seek CoÂ(II)-independent inhibitors, a novel
structural class containing a 2-(pyridin-2-yl)Âquinazoline core has
been discovered. Many compounds in this class potently and selectively
inhibited <i>Hs</i>MetAP1 without CoÂ(II). Subsequently,
we demonstrated that <b>11j</b>, an auxiliary metal-dependent
inhibitor, effectively inhibited <i>Hs</i>MetAP1 in primary
cells. This is the first report that an <i>Hs</i>MetAP1-selective
inhibitor is effective against its target in cells